4.1 Article

Surgical management of metastatic colon cancer: A population-based analysis

期刊

JOURNAL OF GERIATRIC ONCOLOGY
卷 6, 期 6, 页码 446-453

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jgo.2015.08.002

关键词

Colon cancer; Metastasectomy; Epidemiology

向作者/读者索取更多资源

Background: Metastasectomy has a curative potential in colon cancer, but its benefits have not been ascertained in population data. Our objective was to evaluate utilization of metastasectomy in colon cancer and its survival outcomes in groups defined by different age at diagnosis, tumor grade or varying extent of nodal spread. Methods: We extracted data from the Surveillance, Epidemiology and End Results database on adult patients with stage IV colon cancer diagnosed between 2003 and 2011. We analyzed the association of overall survival (OS) with metastasectomy using multivariable Cox models. Results: Among 41,137 patients with stage IV cancer, 26,607 (65%) underwent primary surgery and 5028 (12.2%) underwent metastasectomy. Older patients were less likely to have >= 12 lymph nodes examined in the surgical specimen, but also less likely to have nodal metastases when adequately staged (from 86% for age <50 years to 79% for age 285 years). Metastasectomy was less common in older patients (from 18% for age <50 years to 7% for age >= 85 years). OS after resection was inversely associated with age and nodal involvement. The association of metastasectomy with survival was favorable in all age groups (hazard ratio, HR, 0.68-0.72, P < 0.0001), but it was not significant for those >= 85 years old (HR, 0.92, P = 0.23). It was also favorable regardless of the extent of nodal spread or tumor grade. Conclusions: Resection of metastatic site is favorably associated with survival in patients up to 85 years of age. Older patients undergoing metastasectomy are more likely to be node-negative when adequately staged. (C) 2015 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Functional Status and Survival in Older Nursing Home Residents With Advanced Non-Small-Cell Lung Cancer: A SEER-Medicare Analysis

Michael A. Liu, Tamra Keeney, Alexa Papaila, Jessica Ogarek, Humera Khurshid, Elizabeth Wulff-Burchfield, Adam Olszewski, Emmanuelle Belanger, Orestis A. Panagiotou

Summary: ADL assessment may stratify mortality outcomes among older nursing home adults with NSCLC, and may be a useful clinical consideration in this population.

JCO ONCOLOGY PRACTICE (2022)

Article Oncology

Global Risk Indicator and Therapy for Older Patients With Diffuse Large B-Cell Lymphoma: A Population-Based Study

Mengyang Di, Tamra Keeney, Emmanuelle Belanger, Orestis A. Panagiotou, Adam J. Olszewski

Summary: This study examines the impact of global risk on treatment selection and outcomes among older home care recipients with diffuse large B-cell lymphoma. The study finds that high-risk patients are less likely to receive chemotherapy, have higher rates of mortality, emergency department visits, hospitalization, and intensive care unit admission, and have lower overall survival.

JCO ONCOLOGY PRACTICE (2022)

Letter Hematology

Postibrutinib relapse outcomes for patients with marginal zone lymphoma

Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Xiao-Wei Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Timothy S. Oh, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, Geoffrey Shouse

BLOOD ADVANCES (2023)

Editorial Material Ethics

Unique Ethical and Practical Considerations in the Use of Behavior Contracts for Families of Minors and Minoritized Populations in Pediatric Settings

Aleksandra E. E. Olszewski, Lori Mendelsohn, Erin Talati Paquette

AMERICAN JOURNAL OF BIOETHICS (2023)

Meeting Abstract Hematology

Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study

Narendranath Epperla, Rui Li, Pallawi Torka, Lauren Shea, Reem Karmali, Andrea Anampa-Guzman, Timothy Seijung Oh, Kathryn Lindsey, Irl Brian Greenwell, Sayan Mullick Chowdhury, Kaitlin Annunzio, Beth Christian, Geoffrey Shouse, Alex F. Herrera, Nancy L. Bartlett, Natalie S. Grover, Adam J. Olszewski

Article Hematology

Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles

Diana O. Treaba, Dennis M. Bonal, Anna Chorzalska, Mireia Castillo-Martin, Alissa Oakes, Makayla Pardo, Max Petersen, Christoph Schorl, Kelsey Hopkins, Dean Melcher, Ting C. Zhao, Olin Liang, Eui-Young So, John Reagan, Adam J. Olszewski, James Butera, Douglas C. Anthony, Peter Rintels, Peter Quesenberry, Patrycja M. Dubielecka

Summary: This study evaluated the impact of anthracycline- and cytarabine-based induction chemotherapy on the bone marrow microenvironment in acute myeloid leukemia (AML). Using RNA-seq and histological analysis, the researchers found distinct osteogenic and mesenchymal transcriptome profiles in responders and non-responders to chemotherapy. These findings provide valuable insights into the specific treatment response of AML and may inform optimized therapeutic strategies.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Editorial Material Hematology

Meet the Burkitts: a dark zone family

Adam J. Olszewski

Summary: In this study, whole-genome sequencing was used to analyze 230 cases of pediatric and adult Burkitt lymphomas, aiming to discover genomic subgroups of this rare disease. The researchers employed a consensus clustering algorithm based on somatic mutations, copy number alterations, and structural variants. The classification of Burkitt lymphoma subgroups was improved by comparing and adding 295 DLBCL genomes to the analysis, due to the imperfect diagnostic criteria.
Article Geriatrics & Gerontology

Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: A population-based study

Mengyang Di, Tamra Keeney, Emmanuelle Belanger, Scott F. Huntington, Adam J. Olszewski, Orestis A. Panagiotou

Summary: This study aimed to characterize the prevalence of functional and cognitive impairments, and associations between impairments and treatment among older patients with diffuse large B cell lymphoma (DLBCL) receiving nursing home (NH) care. The study found that NH patients had high rates of functional and cognitive impairments, low rates of chemoimmunotherapy, and poor overall survival. This provides the basis for further research on novel treatment strategies, alternative treatment strategies, and patient preferences in optimizing clinical care and outcomes in this high-risk population.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2023)

Article Oncology

Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study

Ari Pelcovits, Peter Barth, John L. Reagan, Adam J. Olszewski, Vallerie Rosati, Roxanne Wood, Ashlee Sturtevant, Eric S. Winer

Summary: This study evaluated the safety and efficacy of an all-oral regimen of ixazomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma patients. The overall response rate was 58.3% and there were no severe peripheral neuropathy cases. However, 50% of patients experienced grade 3 or greater dermatologic toxicity. Limited enrollment prevented further evaluation of this regimen in newly diagnosed multiple myeloma patients.

ONCOLOGIST (2023)

Letter Hematology

An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy

Faheem Farooq, Justin S. Brandt, Elyce Cardonick, Evgeniya Polushkina, Julie Vose, Sairah Ahmed, Praveen Ramakrishnan Geethakumari, Adam J. Olszewski, Hesham Yasin, Umar Farooq, Nada Hamad, Yong Lin, Charlotte Maggen, Robert Fruscio, Mina Mhallem Gziri, Karina Dahl Steffensen, Frederic Amant, Andrew M. Evens

BLOOD ADVANCES (2023)

Review Oncology

Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma

Ari Pelcovits, Thomas A. Ollila, Adam J. Olszewski

Summary: Cutaneous T-Cell Lymphoma (CTCL) is a complex disease that requires a specialized approach to management. Localized disease can often be treated with topical therapy, while more extensive involvement requires systemic therapies. Recent advancements in immune-based treatments offer potential for longer periods of response with less toxicity.

CANCER MANAGEMENT AND RESEARCH (2023)

Article Hematology

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Adam J. Olszewski, Tycel J. Phillips, Marc S. Hoffmann, Philippe Armand, Tae Min Kim, Dok Hyun Yoon, Amitkumar Mehta, Richard Greil, Jason Westin, Izidore S. Lossos, Javier L. Munoz, Jason Sit, Michael C. Wei, Annie Yang, Vivian Chen, Enkhtsetseg Purev, Donald L. Yee, Ulrich Jaeger

Summary: The study demonstrates promising activity and a manageable safety profile for Mosunetuzumab-CHOP in previously untreated DLBCL patients, suggesting its potential as a first-line combination regimen for DLBCL.

BLOOD ADVANCES (2023)

Article Oncology

Clinical features of patients with MTAP-deleted bladder cancer

Andre L. De Souza, Anthony E. Mega, John Douglass, Adam J. Olszewski, Ece D. Gamsiz Uzun, Alper Uzun, Charissa Chou, Fenghai Duan, Jinyu Wang, Amin Ali, Dragan J. Golijanin, Sheldon L. Holder, Galina G. Lagos, Howard Safran, Wafik S. El-Deiry, Benedito A. Carneiro

Summary: Despite new therapies, advanced urothelial carcinoma still has a poor prognosis. FGFR2 and FGFR3 mutations, PD-L1 expression, tumor mutational burden, and microsatellite instability are predictive biomarkers. Novel biomarkers can improve treatment sequencing and outcomes.

AMERICAN JOURNAL OF CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial

Lihua E. Budde, Adam J. Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K. Nakhoda, Stephen D. Smith, Kathleen Dorritie, Ting Jia, Song Pham, Ling-Yuh Huw, Jing Jing, Hao Wu, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, Julio C. Chavez

Summary: In an ongoing phase 1/2 trial, the combination of mosunetuzumab and polatuzumab vedotin showed a promising overall response rate of 59.2% for second-line treatment in patients with transplant-ineligible or CAR-T-cell-ineligible relapsed or refractory large B cell lymphoma.

NATURE MEDICINE (2023)

Meeting Abstract Hematology

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma

Kaitlin Annunzio, Natalie S. Grover, Rui Li, Daniel Jones, Walter Hanel, Beth Christian, Adam J. Olszewski, Narendranath Epperla

Article Oncology

Longitudinal changes in cognitive and physical function and health-related quality of life in older adults with acute myeloid leukemia

Vijaya R. Bhatt, Christopher Wichman, Thuy T. Koll, Alfred L. Fisher, Tanya M. Wildes, Ann Berger, James O. Armitage, Sarah A. Holstein, Lori J. Maness, Krishna Gundabolu

Summary: A study on older adults with AML receiving chemotherapy showed significant comorbidity burden and functional impairments at baseline, but cognitive and physical function improvements or stability, as well as improved depression scores, were observed in a high proportion of patients at three months post-treatment, indicating success of treatment.

JOURNAL OF GERIATRIC ONCOLOGY (2024)

Correction Oncology

Hospitalization due to adverse drug events in older adults with cancer: A retrospective analysis (vol 14,101540, 2023)

Darren J. Walsh, Laura J. Sahm, Michelle O'Driscoll, Bronagh Bolger, Hitam Ameen, Michelle Hannan, Caitriona Goggin, Anne M. Horgan

JOURNAL OF GERIATRIC ONCOLOGY (2024)

Article Oncology

Risk of dementia among older patients with lymphoma: A Danish nationwide matched cohort study

Eva Futtrup Maksten, Lasse Hjort Jakobsen, Boris Modrau, Hilde Jensvoll, Kristian Hay Kragholm, Judit Meszaros Jorgensen, Michael Roost Clausen, Robert Schou Pedersen, Andriette Dessau-Arp, Thomas Stauffer Larsen, Christian Bjorn Poulsen, Anne Ortved Gang, Peter Brown, Tarec C. El-Galaly, Marianne Tang Severinsen

Summary: The risk of developing dementia is not increased after lymphoma treatment among patients.

JOURNAL OF GERIATRIC ONCOLOGY (2024)

Review Oncology

Self-reported electronic symptom monitoring in older patients with multimorbidity treated for cancer: Development of a core dataset based on expert consensus, literature review, and quality of life questionnaires

P. A. L. Nelleke Seghers, Marije E. Hamaker, Shane O'Hanlon, Johanneke E. A. Portielje, Hans Wildiers, Pierre Soubeyran, Annemarie Coolbrandt, Siri Rostoft

Summary: This study identified a core set of symptoms to monitor in older patients with multimorbidity treated for cancer. These symptoms include those related to cancer, treatment side effects, functional decline, and destabilization of comorbidities. The results provide a basis for guiding symptom monitoring during cancer treatment.

JOURNAL OF GERIATRIC ONCOLOGY (2024)